🔎 Trials Near Me

Beranda › Atrofi Geografis › Arizona

Uji klinis Atrofi Geografis di Arizona

5 studi untuk Atrofi Geografis mencari peserta di lokasi di Arizona.

Kota di Arizona

Teks studi resmi (Bahasa Inggris)

A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

  • Retina Associates Southwest PC, Tucson
Menerima pesertaFase 2/3
Usia 60 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT06635148

A Phase 1/2 Study of the Safety and Efficacy of BRX011 Oral Administration Once Daily in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration

  • Associated Retina Consultants - PHX, Gilbert
  • Associated Retina Consultants, Phoenix
Menerima pesertaFase 1/2
Usia 55 ke atas · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT07029945

A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

  • Associated Retina Consultants - Peoria- Site Number : 8400011, Peoria
  • Retina Macula Institute of Arizona- Site Number : 8400028, Scottsdale
Menerima pesertaFase 1/2
Usia 60 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07215234

A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

  • Barnet Dulaney Perkins Eye Center-Ophthamalogy, Chandler
  • Barnet Dulaney Perkins Eye Center, Phoenix
  • Associated Retina Consultants, Phoenix
  • dan 3 lainnya
Menerima pesertaFase 3
Usia 50 hingga 85 · Semua jenis kelamin · Diperbarui 18 Sep 2026 · NCT06541704

Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD

  • Associated Retina Consultants, Gilbert
  • Associated Retina Consultants, Phoenix
Menerima pesertaFase 2
Usia 55 ke atas · Semua jenis kelamin · Diperbarui 10 Sep 2026 · NCT06659445

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.